TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05800977: A Phase 1b/2 Study of a Anti-CD19/CD20 Bispecific CAR-T Therapy (C-CAR039/Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Sponsor: Shanghai AbelZeta Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 112 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,757,210

Rescue Site Savings

+$5,772,690

Unlock Full NCT05800977 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05800977 Rescue Dossier →